30 June 2020 Image: Glen Carrie In lab tests, virus-like DNA structures coated with viral proteins provoke a strong immune response in human B cells, by Ann Trafton, MIT News Office By folding DNA into a virus-like structure, MIT researchers have designed HIV-like particles that provoke a strong immune… Read More
29 June 2020 Image: Clay Banks Evotec, Samsara BioCapital, KCK have launched Autobahn Labs, a novel virtual incubator partnering with top academic and research institutions to catalyse early-stage drug discovery and development. Autobahn Labs also announced a first-in-kind strategic collaboration with UCLA Technology Development Group to identify and… Read More
Computational modeling yields a protein fragment that could bind to coronavirus spike proteins and destroy them by Anne Trafton, MIT News Office The research described in this article has been published on a preprint server but has not yet been peer-reviewed by scientific or medical experts. Using computational models… Read More
25 June 2020 Dotmatics has agreed to acquire BioBright, an expert in automating the flow of data from laboratory instruments to a secure cloud. BioBright’s solutions enable scientists to automate the collection of data from in-house and externally networked sources, and then standardise and analyse crucial experimental data… Read More
Scientists from AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyse the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2. Prior to an effective… Read More
22 June 2020 Epidarex Capital, an international finance firm, has launched a £102 million fund in Edinburgh to invest in emerging life sciences businesses. The fund will build new life science companies using world-class research and innovation from emerging hubs across the UK, including university spinouts. Typical initial investments… Read More
22 June 2020 SLAS Transformed is an interactive event focused on omics, synthetic biology and genome editing along with applicable implications for the current pandemic. The two-day event runs from 23-24 June 2020, offering 30-minute scientific research presentations, live exhibitor presentations and one-on-one networking sessions. It will span multiple… Read More
AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate drug discovery, has announced that its platform identified dexamethasoneas having high potential for the treatment of COVID-19 in April 2020. AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate… Read More
17 June 2020 This is the second tranche of growth capital loan signed with the European Investment Bank in May 2019. The new funds will be used for the development, manufacture and commercialisation of in vitro diagnostics for infectious diseases Mobidiag, a revenue generating, molecular diagnostics company with… Read More
The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 - Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered regularly-interspaced short palindromic repeats… Read More
Target discovery and drug development what comes after CRISPR? By Benedict CS Cross Volume 21 Issue 2 - Spring 2020 For an area of research as important and impactful as drug discovery, it is surprising how often efforts in this field are directed by short-term trends. We have seen an… Read More
Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 - Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering, has been… Read More
Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace the expectations of ’omicsbased… Read More
Getting a handle on liquids: automation solutions for drug discovery By Helen Stewart-Miller and Thomas Hope The accurate and precise measurement of liquids and the transport of exact volumes between vessels, or from one instrument to another, are processes that constitute the very essence of research. However, while this simple… Read More
By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in… Read More
Fail Early, Fail Fast - A phenotypic rescue approach By Dr Anne-Marie Zuurmond, et al. New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery programme is often lacking. In pharmacological or genetic perturbation studies using complex biological assays,… Read More